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Overexpression of TFAP2C in invasive breast cancer correlates
with a poorer response to anti-hormone therapy and reduced
patient survival
Abstract
The AP-2gamma transcription factor encoded by the TFAP2C gene is a member of a family of
homologous DNA binding proteins that play essential roles during vertebrate embryogenesis but show a
restricted pattern of expression in the adult. Elevated expression of the AP-2alpha and AP-2gamma
family members has been associated with a number of neoplasms, particularly breast cancer. Here we
present an exploratory immunohistochemical study of an archival primary breast tumour series (n = 75)
with parallel clinicopathological data using a new, well-characterized antibody to AP-2gamma.
Heterogeneous, exclusively nuclear expression of AP-2gamma was found in the epithelial and
myoepithelial compartments of normal breast and within tumour epithelial cells. In the breast cancer
series, the most notable association was a correlation between elevated levels of AP-2gamma and
shortened patient survival (p = 0.0009*). This relationship was also conserved in ER-positive and
ErbB2-negative patients; sub-groups generally considered to have a relatively good prognosis. When
patient data for survival and duration of treatment response on anti-hormone therapy were examined by
multivariate analysis, AP-2gamma was revealed in this study to be an independent predictor of outcome
for both survival (p = 0.005) and response to anti-hormone therapy (p = 0.046). Studies using in vitro
models confirmed that while tamoxifen response is associated with lower levels of AP-2gamma,
acquisition of resistance to this and other anti-hormone measures (eg faslodex or oestrogen deprivation)
is associated with high levels of nuclear AP-2gamma. Together these data suggest that elevated tumour
AP-2gamma expression can contribute to the failure of cells to growth arrest following anti-hormone
treatment and lead to sustained growth and poorer patient outcome. 
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ABSTRACT 
The AP-2γ transcription factor encoded by the TFAP2C gene is a member of a 
family of homologous DNA binding proteins that play essential roles during 
vertebrate embryogenesis but show a restricted pattern of expression in the adult. 
Elevated expression of the AP-2α and AP-2γ family members has been 
associated with a number of neoplasms, particularly breast cancer.  Here we 
present an exploratory immunohistochemical study of an archival primary breast 
tumour series (n=75) with parallel clinicopathological data using a new, well-
characterised antibody to AP-2γ.  Heterogeneous, exclusively nuclear expression 
of AP-2γ was found in the epithelial and myoepithelial compartment of normal 
breast and within tumour epithelial cells.  In the breast cancer series, the most 
notable association was a correlation between elevated levels of AP-2γ and 
shortened patient survival (p=0.0009*).  This relationship was also conserved in 
ER positive and ErbB2 negative patients; sub-groups generally considered to 
have a relatively good prognosis. When patient data for survival and duration of 
treatment response on anti-hormone therapy were examined bymultivariate 
analysis, AP-2γ was revealed in this study to be an independent predictor of 
outcome for both survival (p=0.005) and response to anti-hormone therapy 
(p=0.046). Studies using in vitro models confirmed that while tamoxifen response 
is associated with lower levels of AP-2γ, acquisition of resistance to this and other 
anti-hormone measures (e.g. faslodex or oestrogen deprivation) is associated with 
high levels of nuclear AP-2γ.  Together these data suggest that elevated tumour 
AP-2γ expression can contribute to the failure of cells to growth arrest following 
anti-hormone treatment and lead to sustained growth and poorer patient outcome. 
 
Keywords: AP-2 transcription factors, breast cancer, tamoxifen resistance, 
prognostic markers, immunocytochemistry 
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INTRODUCTION  
The AP-2 family of developmentally regulated transcription factors consists of five 
members, AP-2α-ε, [1-4] that are expressed during vertebrate embryogenesis in 
overlapping but distinct patterns of expression, especially within tissues 
undergoing morphogenesis [1].  The importance of these expression patterns has 
been borne out by homologous gene inactivation studies in mice. Mice lacking AP-
2α showed multiple defects in the development of neural crest-derived tissues 
such as the cranio-facial skeleton [5-7] and the outflow tract of the heart [8].  Loss 
of AP-2β led to failed terminal kidney differentiation [9].  In contrast, AP-2γ was 
shown to be absolutely required within the extra-embryonic lineages for early post-
implantation development [10, 11].  The more recently described AP-2δ and AP-2ε 
genes are thought to play more specialised roles in embryo brain and CNS [3, 12]. 
 
Expression of AP-2 proteins in normal adult tissues is much more restricted. 
However, a large number of studies have clearly demonstrated expression of AP-
2α and AP-2γ, in particular, in a variety of solid tumours, including breast cancer 
where transcriptional targets include ERBB2, oestrogen receptor (ERα), and 
p21WAF1/CIP1 (reviewed [13]).  Expression of AP-2α in breast cancer has generally 
been associated with a favourable outcome.  For example, we and others have 
found a direct correlation between AP-2α  and expression of ERα and the cell 
cycle inhibitor p21WAF1/CIP1, coupled with a lower rate of proliferation [14, 15]. AP-
2α staining was found to be highest in normal breast epithelia with a decline in 
levels in samples of DCIS and the lowest expression in cases of invasive cancer 
[14]. Reduced nuclear AP-2α staining has also been associated with more 
aggressive, high-grade breast tumours [16] andTFAP2A mRNA expression has 
 4
been inversely correlated with tumour grade [17].  In summary, AP-2α expression 
in tumours has been associated with favourable prognostic markers which has led 
to the suggestion that this factor may be acting in a tumour suppressive role, in 
breast cancer and in other cancer types (reviewed [13]).  
 
In contrast, elevated tumour levels of AP-2γ have largely been correlated with an 
adverse phenotype and increased disease progression.  High levels of AP-2γ were 
found in testicular cancer [18], germ cell tumours [18, 19], advanced stages of 
ovarian cancer [20] and certain stages of melanoma [21]. In breast cancer, data 
mining of microarray expression studies has shown an association between high 
levels of TFAP2C mRNA and higher clinical grade and shorter survival times [17, 22]. 
However, as reviewed recently [13], the few studies that examined protein levels in 
breast cancer rarely used specific immunological reagents against AP-2γ, leading to 
apparently conflicting observations and a lack of clarity as to its overall role. In the 
current exploratory study, therefore, we have developed and carefully characterised a 
monoclonal antibody against AP-2γ and used it to examine expression levels in a 
series of primary invasive breast tumour samples (previously assayed for AP-2α [14]) 
to determine if AP-2γ correlates with outcome. We have then further explored the 
relationship between AP-2γ endocrine response using breast cancer models. 
 
METHODS 
Cell lines 
Acquired tamoxifen-resistant derivatives of MCF-7 (TamR) and T47D (T47D-R), 
MCF-7 cells with acquired resistance to faslodex (FASR-LT) or to severe 
oestrogen and growth factor deprivation (MCF-7X) [23-26] were examined in vitro. 
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Hormonal manipulation was carried out by supplementing standard growth 
medium (phenol-red-free RPMI medium containing 5% charcoal-stripped foetal 
calf serum, 200mM glutamine,10 IU/ml penicillin, 10ug/ml streptomycin) with 
either 10-8 β-oestradiol, 10-6M 4-hydroxytamoxifen or 10-7M faslodex  for 48 hours 
prior to cell harvest. Log-phase MCF-7, T47D, ZR75-1, MDAMB453 and 
MDAMB436 were also prepared for assay optimisation. For 
immunocytochemistry, cells were concentrated by centrifugation, transferred to 
2% low melting point agarose/PBS at 37oC to form solid pellets, fixed in 4% formal 
saline and embedded in paraffin wax. Pellets were cored and assembled in 
replicates using a tissue arrayer forming a composite array which was sectioned 
at 5μM for immunostaining. 
 
Generation of AP-2γ monoclonal antibody, 6E4 
A 30 kDa AP-2α/γ fusion protein (see Figure 1A) was expressed in bacteria and 
purified [27]. Balb/c mice received  four subcutaneous injections of purified protein 
(25μg/injecton) with adjuvant at four weekly intervals.  
 
Electromobility shift assays (EMSA) and Western blotting  
AP-2 proteins, synthesized in vitro (T’N’T kit; Promega) from wild-type and mutant 
AP-2 clones [28], were used in EMSA assays as previously described [29]. IVT 
proteins or whole cell lysates (10μg/ lane) were blotted to Hybond-ECL membrane 
(Amersham) and probed with 6E4. Chemiluminescent detection of horseradish 
peroxidase-conjugated secondary antibodies was performed using the West 
Femto Maximum Sensitivity Substrate kit (Pierce). Loading was controlled by 
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blotting for nuclear antigens Ku-70 (C-19, Santa Cruz) or PCNA (P10, Santa 
Cruz).  
 
Clinical samples 
A series of 75 formalin-fixed, paraffin-embedded primary tumours obtained from 
patients (age range 25-77, median 53.5) with histologically proven breast cancer 
presenting for surgery at Nottingham City Hospital between 1984-1987 was 
investigated. This is a well-characterised, historical breast cancer series with 
approval for use without further patient consent (approved ethics application, 
Nottingham Research Ethics Committee 2; C108030; [30]). All patients received 
systemic antihormonal therapy for locally-advanced primary carcinoma (>5cm) or 
metastatic disease, or for recurrence after surgery alone. Premenopausal patients 
(n=23) received ZoladexR (3.6mg depot/28days) alone or with tamoxifen (20mg 
twice daily), while postmenopausal (n= 52) received only tamoxifen. None of the 
patients had received any form of adjuvant cytotoxic therapy or prior endocrine 
treatment.  All patients had lesions assessable for response quality at 6 months 
according to UICC criteria (responders (CR, PR, SD) n=28; progressors n=47). 
Survival and duration of anti-hormone response were measured from 
commencement of anti-hormone to death or progression on therapy respectively. 
Median follow-up was 16 months (see supplementary information for further 
details). Additional samples assayed were: i) pure DCIS (n=20; comedo or non-
comedo) of known ErbB2 status and ii) normal breast reduction mammoplasty 
material (n=20).  
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Optimised Immunohistochemistry assay, scoring and analysis 
All sections were de-waxed, re-hydrated and endogenous peroxidases were 
blocked using 3% hydrogen peroxide (5 min). Sections were microwaved (0.01M 
citrate buffer, pH 6 for 30 min at 560W) to aid antigen retrieval.  All subsequent 
steps were at 25oC. A 1/35 dilution of 6E4 conditioned medium was applied 
overnight and, after washing, secondary antibody (biotinylated anti-mouse 
immunoglobulins in 1% BSA/PBS; Biogenex Super Sensitive “link”) was applied 
(1/40; 60 min).  Tertiary reagent (streptavidin peroxidase in 1% BSA/PBS; 
Biogenex Super Sensitive “label”) was applied (1/40; 60 min) followed by 
diaminobenzidine/hydrogen peroxide chromogen for 10 min with methyl green 
(0.5%) counterstaining.  Negative controls were incubated with mouse isotype-
specific control immunoglobulins(Dako). 
 
All sections were assessed simultaneously by two observers blinded to the clinical 
data using a dual-viewing light microscope with x40 lens.  Areas of tumour-
associated-normal/-DCIS were excluded from the assessment of invasive tumour 
immunostaining. Matched control slides were checked for non-specific binding 
before assessing the nuclear staining intensity and percentage positivity of the 
tumour epithelial cells (minimum of 2000 tumour cells evaluated).  The data were 
used to construct an AP-2γ histopathology score (HScore; range 1-300) for each 
tumour specimen as detailed previously [31], with epithelial staining also 
examined in DCIS and normal breast sections.  
 
Mann-Whitney U-test was used to compare AP-2γ levels in comedo versus non-
comedo DCIS and to examine tumour AP-2γ staining in relation to ER or ErbB2 
status, response quality, menopausal status, disease site (locally-advanced vs. 
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metastatic disease), tumour grade (1/2 vs. 3), PR and AP-2α/β status [14]. 
Univariate analysis was performed using the Kaplan-Meier method with a log rank 
test . Multivariate analysis was performed using Cox's Proportional Hazards 
model, controlling for co-variates as listed in the Results. Univariate and 
multivariate analysis addressed AP-2γ impact on survival from initiation of therapy 
or on duration of therapeutic response, before and after subdivision for (i) ER or  
(ii) ErbB2 status.  p<0.05 was considered significant (*). No adjustments for 
multiple testing were made due to the exploratory nature of the study. 
 
 
Results 
Characterisation of AP-2γ monoclonal antibody  
A bacterially expressed AP-2α/γ fusion protein (Figure 1A) was used to generate 
an immunogen for injection into mice. One mouse with a weak response against 
AP-2α but a strong response against AP-2γ was selected for monoclonal antibody 
generation.  Of the hybridoma lines subsequently derived, 6E4 interacted strongly 
and specifically with AP-2γ with no cross reaction to other AP-2 family members 
(Figure 1B). The epitope was mapped within the C-terminal 20 amino acids of  
AP-2γ, as shown by "supershifting" EMSA: migration of protein/DNA complexes 
with AP-2γ mutant ΔN220C430 was not altered by addition of 6E4 (Figure 1C, 
compare odd and even lanes).  6E4 does not detect murine AP-2γ (data not 
shown) which differs by two amino acids within this C-terminal region.  Western 
blotting (Figure 1D) of lysates from breast tumour-derived lines of  known AP-2γ 
expression status [32] showed a clear 50 kDa band in expressing lines (MCF-7, 
T47D, ZR75-1) which was absent in non-expressing cells (MDAMB453 and 
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MDAMB436).  There were essentially no other cross-reacting species, indicating 
that 6E4 is a highly specific reagent suitable for evaluation of AP-2γ 
immunochemistry. 
 
AP-2γ Immunocytochemistry 
Paraffin sections of cell pellets from breast tumour-derived lines were used to 
initially optimise AP-2γ staining.  Intense nuclear staining was only present in AP-
2γ positive lines (MCF-7, HScore = 180; T47D, HScore = 130; ZR75-1, HScore = 
110). Lines negative for AP-2γ exhibited virtually no nuclear staining (MDAMB453; 
HScore = 35 and MDAMB436; HScore = 15). This staining profile closely reflected 
the relative band intensity observed by Western blotting (Figure 1D) thus 
validating the immunostaining methodology.   
 
A cohort of 75 primary breast tumours which had previously been examined for 
expression of a number of other markers, including AP-2α/β [14], was assayed for 
AP-2γ expression.  A continuum of nuclear immunostaining levels between the 
samples was observed (HScore range 20-230) with no obvious cut-off point in 
staining distribution (see supplementary figure).  The median (HScore ≥ 120) was 
used to define those tumours with substantial AP-2γ “positivity” versus “negative” 
(low staining) samples for univariate analyses, but absolute HScore values were 
used for all other analyses.  
 
Tumour epithelial staining was heterogeneous and entirely confined to the nuclei: 
no cytoplasmic immunostaining was apparent and surrounding stromal cells and 
blood vessels were negative (see Figure 2A). A proportion of the samples 
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contained adjacent regions of tumour-associated DCIS (TAD; n = 19; see Figure 
2B) and/or tumour-associated normal epithelium (TAN; n= 32) which were also 
positive for AP-2γ expression. To examine these staining patterns further, we 
stained twenty cases of pure DCIS (10 comedo, 10 non-comedo) and saw higher 
AP-2γ staining (p = 0.015*) in the comedo (Median HScore = 95, range = 40-170; 
Figure 2C) compared to the non-comedo samples (Median HScore = 23.5, range 
= 2-125; Figure 2D). Notably, the former group were enriched for ErbB2 (50% 
overexpressors) relative to their non-comedo counterparts (no overexpressors). 
Twenty samples of normal breast tissue from reduction mammoplasty patients 
were also examined. Staining was again nuclearand heterogeneous with 
apparently a higher proportion of intensely staining cells than seen in invasive 
tumours or DCIS (Figure 3); this was particularly prominent and more 
homogeneous in the myoepithelium (see inset, Figure 3).  
 
 
Elevated AP-2γ expression is associated with reduced patient survival 
Examination of AP-2γ expression levels in this tumour series revealed a 
correlation between elevated AP-2γ and shortened survival from initiation of 
therapy (Table I).  We found a median survival of 39 months for cases with low 
AP-2γ as compared to 15 months for those with high AP-2γ expression 
(p=0.0009*).  This is illustrated in Figure 4, where a marked separation in survival 
curves is evident after 20 months. Clinically, patients are now stratified according 
to ER and ErbB2 status; we thus examined AP-2γ in the ER positive and the 
ErbB2 negative patient sub-groups, noting a significant relationship between 
higher expression and shortened survival in both (Table I).  These relationships in 
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this patient series are intriguing given that ER positivity and ERBB2 negativity are 
generally considered as favourable prognostic indicators in breast cancer and 
suggest that nuclear AP-2γ positivity may be a marker of poorer outlook in this 
heterogeneous disease.  
 
We also observed increased AP-2γ associated with shortened time to progression 
(TTP; 3 versus 9  months for AP-2γ “negative”; p=0.04*). Ag PubMed ain, this 
relationship was significant in ErbB2 negative patients (3 versus 10 months for 
AP-2γ high and low expressors respectively; p=0.002*), where examination of 
response quality at 6 months alsorevealed responders had lower AP-2γ  than 
progressors (median HScore=95 and 135 respectively; p=0.013*).  
 
Survival and TTP on anti-hormone therapy were additionally examined by 
multivariate analysis using Cox proportional hazards model.  In addition to  
AP-2γ, co-variates considered for inclusion were ER, PR and ErbB2 status, site, 
grade and menopausal status. Univariate analysis revealed parameters 
significantly associated with survival in the series were grade (p=0.003), site 
(p<0.001) and ER status (p<0.001). These parameters were also significant in 
relation to TTP (p<0.001, p<0.001 and p<0.001 respectively) but additional factors 
were menopausal (p=0.005) and PR status (p=0.017). ErbB2 was not significant 
in either analysis. Significant co-variates were subsequently used to build survival 
and TTP models in multivariate analysis (Table II).  AP-2γ was an independent 
predictor of poorer survival, (p=0.005*) and also of decreased duration of 
response on anti-hormone therapy (p=0.046*).  The association between 
increased hazard ratio and AP-2γ was retained in ErbB2 negative disease for 
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survival (p=0.002*) and duration of response (p=0.002*). In ER positive patients, 
AP-2γ again related to reduced survival (p=0.048*), although associations with 
TTP were lost in this small series.  
 
AP-2γ expression in in vitro models is associated with anti-hormone resistance 
TFAP2C has been shown to be a modestly oestrogen-responsive gene [33]. To 
explore the relationship further between AP-2γ levels and response versus resistance 
to anti-hormone therapy, we used a panel of well-characterised in vitro breast cancer 
models established in ER positive, ErbB2 negative (by IHC criteria) cell lines. 
Western blotting demonstrated that AP-2γ levels declined in MCF-7 cells treated with 
tamoxifen for 48 hours compared to cells maintained in oestrogen-containing media 
(Figure 5, compare lanes 2 and 1). Interestingly, the ER-positive, tamoxifen resistant 
(TamR) derivative of these cells showed fully-restored levels of AP-2γ which were 
maintained even when these cells were treated with the pure anti-oestrogen, faslodex 
(Figure 5, compare lanes 3 and 4).  
 
Localisation of AP-2γ in in vitro models of anti-hormone resistance was also 
investigated by immunostaining paraffin-embedded pellet arrays.  As shown in Figure 
6, hormonally manipulated MCF-7 and also T47D cells expressed varying levels of 
AP-2γ but in all cases the protein remained predominantly nuclear. While 17β-
estradiol  was stimulatory, acute addition of tamoxifen again reduced AP-2γ staining 
in MCF-7 cells (Figure 6, compare panels A, B and C). However, cells which had 
become refractory to tamoxifen showed fully-restored wild-type levels of nuclear AP-
2γ that were again maintained when these cells were exposed to faslodex (Figure 6, 
compare Panels D, E with A). T47D cells extensively cultured in tamoxifen also 
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expressed wild-type levels of AP-2γ (Figure 6, panels H and I). Moreover, the MCF-
7X model (resistant to severe oestrogen deprivation) and acquired faslodex resistant 
cells also displayed readily-detectable levels of nuclear AP-2γ, with particularly 
substantial levels in the former (Figure 6, compare panels F, G and A).  
 
Thus, while AP-2γ levels clearly fall during tamoxifen response, these experimental 
models demonstrate that breast cancer cells re-instigate substantial levels of nuclear 
(and therefore potentially active) AP-2γ when they become anti-hormone resistant. 
Together with our observational study associating higher AP-2γ levels with poorer 
outcome in anti-hormone treated patients, these data suggest a potential contribution 
for AP-2γ in the biology of diverse, anti-hormone-resistant states. 
 
DISCUSSION 
Studies examining expression of the AP-2γ transcription factor in tumours have 
often used reagents that are either poorly characterised or which recognise 
multiple AP-2 family members [13]. Here we describe the generation and 
extensive characterisation of a specific monoclonal antibody against AP-2γ and its 
application to examine factor expression levels in normal and malignant breast 
tissue.  Strong AP-2γ staining was noted in the nuclei of both epithelial and 
myoepithelial cells of the pure normal breast samples, with a marked mosaic 
expression in normal luminal epithelial cells (Figure 3), which reflects findings in 
the terminal end buds (TEBs) of the developing mouse mammary gland.  TEBs 
ultimately form the ductal network and contain two cell populations: body cells 
which will form ductal epithelial tissue and cap cells which are the progenitors of 
the myoepithelial layer.  A mosaic, rather than uniform, pattern of expression for 
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AP-2γ was noted in both cell types in mouse TEBs [34].  
 
Compared to the level of staining in normal tissue, we see an apparent reduction 
in AP-2γ nuclear staining between normal epithelial cells and either DCIS or 
invasive tissue. Similar data was noted from microarray studies where AP-2γ was 
shown to be expressed at a significantly higher level in samples of normal tissue 
or benign disease than in cases of ductal carcinoma  ([22, 35]; p= 0.002 and 
0.009 respectively). Our most striking finding however, is that, for those patients 
whose tumours retained high levels of nuclear AP-2γ expression, there appears to 
be an association with reduced patient survival from initiation of therapy in this 
series (Figure 4). This relationship is retained in ER positive and ErbB2 negative 
cases, two patient sub-groupings generally considered to have a relatively good 
prognosis in breast cancer.  Since high levels of AP-2γ occur in normal breast 
epithelial cells, elevated expression of this factor per se is unlikely to be a tumour 
initiating event. However, our data imply a positiverole for this factor in facilitating 
adverse behaviour of cancers that arise in AP-2γ expressing epithelial cells. Thus, 
AP-2γ may prove to be a marker for patients with an otherwise favourable 
prognosis who fail to respond to therapy. In support of this, univariate and 
multivariate analyses indicated that AP-2γ status was an independent predictor of 
poor outcome, particularly for survival, but also for progression on anti-hormone 
therapy in this series. 
 
Few previous reports have specifically examined AP-2γ expression in breast cancer 
but, in agreement with this study, a qPCR analysis of 38 primary breast tumours 
found a significant association between elevated TFAP2C mRNA and reduced 
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disease-free survival, although an association with overall survival was not 
observed [36].  Two other studies using different polyclonal AP-2γ antibodies failed 
to find a link with outcome. One study focused on patients with early-stage disease 
treated with lumpectomy [15] and in the second study the commercial antibody 
employed apparently only stained the myoepithelial compartment [37].  In contrast, 
using gene expression profiling, TFAP2C mRNA expression was associated with 
advancing clinical grade (p<0.002, [17]). It was also found to be significantly higher 
in patients who died within 5 years of breast cancer compared to those patients who 
were still disease free after 5 years ([22]; p=0.0177), while AP-2α mRNA expression 
levels were not significantly different between these two patient groups.    
 
Our study further highlights the opposing roles seemingly played by the two AP-2 
family members in breast cancer. AP-2 factors can regulate expression of  the cell 
cycle inhibitor p21WAF1/CIP1 and  ERα [1, 13] and for AP-2α this relationship may 
underlie associations between elevated levels of this factor and an indolent breast 
cancer phenotype.  In contrast, elevated AP-2γ expression has been shown here to 
be an independent predictor of poorer survival, where its expression did not relate to 
AP-2α/β status as previously determined for this series [14]. Interestingly, although 
mammary-directed  overexpression of AP-2γ in transgenic mice did not lead to 
tumour development, marked epithelial hyperplasia was observed [38] implicating 
AP-2γ in the promotion of breast epithelial cell proliferation.  
 
High levels of nuclear AP-2γ may also be associated with an anti-hormone resistant 
phenotype, as suggested by our clinical and in vitro findings and also supported by a 
recent study thatexamined AP-2γ levels within a series of ER+ patients with known 
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response to tamoxifen. Multivariate analysis revealed AP-2γ to be an independent 
marker of resistance to tamoxifen, particularly in postmenopausal patients [39].  
Failure of, or resistance to, anti-hormone therapy remains a major problem in the 
clinical management of breast cancer and several mechanisms have been proposed 
to account for this resistance that can equate with poor prognosis [40]. As 
exemplified by our TamR models [23, 41], essentially all of these mechanisms lead to 
the activation of alternative signalling pathways that bypass cell cycle arrest and 
allow cells to continue to proliferate and progress to more aggressive states. In ER+ 
patients, AP-2γ as a ligand-activated ERα target gene [33] would be expected to be 
down-regulated by tamoxifen.  However, poor anti-hormone response in tumours with 
high nuclear AP-2γ might be associated with failed ERα regulation of TFAP2C 
transcription. In support of this, we have shown (Figures 5 and 6) that ER+, TamR 
cells no longer down-regulate AP-2γ expression in the presence of tamoxifen and 
instead express high levels of nuclear, potentially active protein. Restored nuclear 
levels of AP-2γ were also observed in lines resistant to faslodex or severe oestrogen 
deprivation, suggesting that the prevailing AP-2γ level in all these models maintains a 
gene expression profile that contributes to the failure of the cells to growth-arrest 
following anti-oestrogen treatment. By extension, breast tumours that overexpress  
AP-2γ may similarly sustain growth during therapy contributing to the poor patient 
outcome observed in the tumour series.   
 
Since only 75 patients were examined in this study, it must be deemed exploratory, 
where future confirmatory studies in larger clinical breast cancer sets with 
associated endocrine response and survival data will be imperative. Nevertheless, 
the findings of the present study are clearly important since they suggest that AP-2γ 
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expression may be an indicator of reduced patient survival in breast cancer and that 
this factor therefore plays an opposite role to that of AP-2α in this disease. AP-2γ 
expression may also equate with a lack of response to anti-hormonal therapy, as 
supported by our in vitro findings.  
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TABLES 
 
Table I: Median survival  
Patient 
Group p_value AP-2γ level n= 
Median 
survival 
(months) 95% CI 
ALL  0.0009 Low AP-2γ 33 39 16.1 to 61.9 
  High  AP-2γ 42 15 3.4 to 26.6 
      
ER +ve 0.0055 Low AP-2γ 21 44 31.0 to 57.0 
  High  AP-2γ 24 27 20.9 to 33.0 
      
ErbB2 -ve 0.0002 Low AP-2γ 27 44 35.9 to 52.1 
    High  AP-2γ 28 15 0.5 to 29.5 
      
Univariate analysis examining the relationship between AP-2γ expression level (relative to the 
median HScore) and survival from initiation of therapy in three patient groups. CI = confidence 
interval. 
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Table II: Summary of multivariate statistics for Cox regression models 
 Survival 
 Predictor 
Hazard Ratio        
(95% CI) p_value
        
All Patients AP-2γ 1.41[1.1 - 1.79) 0.005 
(n=74, events=62) ER status 2.3 [1.27 - 4.16) 0.006 
 Site 2.82 [1.5 - 5.3) <0.001 
 Grade  - ns 
    
ER +ve Patients AP-2γ 1.34 [1 - 1.78) 0.048 
(n=44, events=34) Site 2.6 [1.2 - 5.2) 0.008 
 Grade  - ns 
    
ErbB2 -ve Patients AP-2γ 1.7 [1.22 - 2.39) 0.002 
(n= 55, events=45) ER status 2.3 [1.14 - 4.63) 0.02 
 Site 2.66 [1.35 - 5.21) 0.005 
 Grade  - ns 
        
    
 Time to Progression 
 Predictor 
Hazard Ratio        
(95% CI) p_value
        
AllPatients AP-2γ 1.28 [1 - 1.62) 0.046 
(n= 73, events=61) ER status 3.26 [1.77 - 6.02) <0.001 
 Site 3.14 [1.71 - 5.73) <0.001 
 Grade 2.11 [1.18 – 3.7)  0.012 
 PR status  - ns 
 Menopausal status  - ns 
    
ErbB2 -ve Patients AP-2γ 1.77 [1.24 - 2.54) 0.002 
(n=54, events=45) ER status  - ns 
 Site 3.8 [1.82 - 8.01) <0.001 
 Grade 2.1 [1.08 - 4.09) 0.029 
 PR status  -  ns 
  Menopausal status  - ns 
    
Multivariate analysis using absolute HScore values for AP-2γ expression in relation to survival from 
initiation of therapy to time to progression. Hazard ratio and CIs for AP-2γ should be interpreted as 
the increase in risk associated with an increase of 1 SD in the co-variate (mean = 113; SD = 45.5; 
ns = not significant). Cut points for positive status were: ER HScore ≤0.05, PR Hscore ≤0.02, ErbB2 
overexpression of membrane staining. 
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FIGURE LEGENDS 
Figure 1: Specificity of 6E4 for AP-2γ.  A) Fusion protein antigen consisting of the 
truncated N-terminus of human AP-2α (aa 165 to 223) fused to the C-terminal 
sequence of human AP-2γ (aa 278-440). An initiator Met was engineered at the 
start (in bold); the sequences switch within the AP-2 basic domain at a common 
Leu residue (underlined). B) Wild-type (wt) AP-2α, β and γ factors, plus the ΔN220 
mutant of AP-2γ, were synthesised in vitro (IVT), blotted to membrane and probed 
with hybridoma 6E4. C) EMSA assay of IVT protein from AP-2γ wt (lanes1-2), 
ΔN220 (lanes 3-4) or ΔN220C430 (lanes 5-6) bound to a consensus AP-2 binding 
site probe in the presence (lanes 2, 4, 6) or absence (lanes 1, 3, 5) of 6E4. D) 
Whole cell extracts (10μg/lane) from AP-2γ positive (lanes 2-4) and negative (lanes 
5-7) cell lines (all breast tumour-derived except HepG2, a known AP-2 negative 
liver carcinoma line) were separated by SDS-PAGE and blotted to membrane.  Wt 
AP-2γ IVT protein was used as a size marker (lane 1). The blot was probed 
sequentially with 6E4 and for Ku-70 (loading control).  Migration of size markers is 
indicated on the left. 
 
Figure 2: Immunohistochemical staining patterns for AP-2γ in breast tumours.  
Examples of staining with antibody 6E4 in formalin-fixed, paraffin-embedded breast 
tumours (panels A and B) and pure DCIS (panels C and D); all original 
magnification x20.  A) Invasive ductal carcinoma with positive nuclear staining for 
AP-2γ surrounded by negative stroma; B) AP-2γ positive invasive tumour and 
associated DCIS (arrowed) with negative stroma. Representative staining in 
comedo (C) and non-comedo (D) DCIS. 
 
Figure 3: Immunohistochemical staining patterns for AP-2γ in normal breast. 
Staining of epithelial and myoepithelial cells in normal ducts from a reduction 
mammoplasty sample (original magnification x20). Inset = detail from a duct 
showing intense staining in the myoepithelial layer (M) and more heterogeneous 
staining of the luminal (L) layer. 
 
Figure 4: Correlation between AP-2γexpression and poorer prognosis in 
invasive breast tumours.  Kaplan-Meier survival curve for AP-2γ expression  
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≥ (High γ) versus < (Low γ) the median HScore of 120.  The two-sided p value was 
calculated using log rank testing. 
 
Figure 5: Expression of AP-2γ in wild-type and tamoxifen-resistant MCF-7 
cells. Western blot of whole cell lysates (10μg/lane) from wild-type MCF-7 cells 
grown in oestrogen-containing media (lane 1) or with 4-OH tamoxifen treatment for 
48 hours (lane 2) compared with acquired tamoxifen resistant (TamR) cells 
maintained in 4-OH tamoxifen-containing medium alone (lane 3) or supplemented 
with Faslodex for 48 hours (lane 4). The blot was probed sequentially with 6E4 and 
for PCNA (loading control) as indicated. 
 
Figure 6: AP-2γ remains nuclear in hormonally manipulated breast cancer cells 
and their anti-hormone resistant variants.  Immunohistochemical staining for AP-
2γ in wild-type and acutely or chronically hormone manipulated MCF-7 and T47D 
cells. Wt MCF-7 cells in 5% stripped serum experimental medium (A) or 
supplemented with β-oestradiol (B) or 4-OH tamoxifen (C). Acquired tamoxifen 
resistant MCF-7 cells (TamR) in the presence of 4-OH tamoxifen (D) or with faslodex 
(E). MCF-7 cells with acquired resistance to faslodex (F) or MCF-7X cells resistant to 
severe oestrogen and growth factor deprivation (G). Wt (H) andacquired tamoxifen-
resistant (I) T47D cells. Original magnification x40.  
 
Supplementary Figure: Distribution curve of AP-2γ immunostaining in the 
breast tumour series.  The graph records the AP-2γ HScore (range 20 – 230) 
assigned to 75 primary breast tumours. Median HScore = 120. 
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Additional information about the patient series (for on-line publication) 
 
The study series is a historic, mixed patient group comprising: 
(i) patients presenting with primary disease that was either locally-advanced 
(i.e. with large tumours >5cm) or metastatic who were treated with surgery 
immediately followed by endocrine therapy.  
(ii) patients presenting with primary disease that, following surgical treatment 
alone, recurred with metastatic disease. These patients were then treated with 
endocrine therapy for this metastatic disease.  
These samples have been used in many immunohistochemical studies to  explore if 
there is a relationship between the clinical impact of first exposure to endocrine 
therapy (including survival measured from initiation of treatment) and the biomarker 
under test (in this instance AP-2γ) as measured in the primary tumour. 
 
 At the time of accumulation of this series (1984-1987), the prevailing view was that 
adjuvant endocrine therapy did not affect survival [1] and this did not become routine 
practice until the Oxford overview [2], explaining why this study also includes patients 
initially treated with surgery only for their primary disease.  During this period patients 
with ER negative disease were also considered for a trial period on endocrine 
therapy, as up to 10% response rates were occasionally observed. Thus, all patients 
in the study were treated with tamoxifen-based regimes, as determined by 
menopausal status (see article text). Since 90% of the ER- patients did not respond 
to endocrine therapy they may have been considered for chemotherapy once they 
progressed. However, there is no detailed log available for the chemotherapeutic 
regimens that might have been subsequently employed or indeed which, if any, ER- 
patients received such treatment. Moreover, since ErbB2 was not routinely measured 
at the time (this was examined later for this series as an exploratory marker), 
potential use of chemotherapy cannot be extrapolated from this status.   
 
Further data were available for this series including patient age, menopausal status, 
disease site (locally advanced versus metastatic disease), tumour type and grade  
(nuclear pleomorphism, tubular differentiation, mitotic activity), PR and ER status 
(ER+ n=45; ER- n=30), as well as proliferative capacity (Ki67) and 
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immunohistochemical expression of ErbB2 plus AP-2α/β  staining from previous 
study of this series (see [3, 4] and references therein). Information about the number 
of metastatic sites and tumour size was not available. Variables not found to be 
significant from initial univariate analysis were excluded from further investigation. 
Notably, we have compared the data on AP-2α and AP-2γ expression levels in this 
patient series: 63 samples had an HScore available for both markers but there was 
no significant relationship in the All, ER+/- nor ErbB2+/- patient groups. Thus, the 
association we report here between AP-2γ and survival appears (given the patient 
set size) to be entirely independent of AP-2α expression level. 
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